ES2164584A1 - Terapia con cannabinoides para el tratamiento de tumores cerebrales. - Google Patents

Terapia con cannabinoides para el tratamiento de tumores cerebrales.

Info

Publication number
ES2164584A1
ES2164584A1 ES200000323A ES200000323A ES2164584A1 ES 2164584 A1 ES2164584 A1 ES 2164584A1 ES 200000323 A ES200000323 A ES 200000323A ES 200000323 A ES200000323 A ES 200000323A ES 2164584 A1 ES2164584 A1 ES 2164584A1
Authority
ES
Spain
Prior art keywords
cannabinoids
treatment
brain tumors
therapy
cerebral tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES200000323A
Other languages
English (en)
Inventor
Pastor Manuel Guzman
Garcia Crsitina Sanchez
Roperh Ismael Galve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Original Assignee
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Complutense de Madrid filed Critical Universidad Complutense de Madrid
Priority to ES200000323A priority Critical patent/ES2164584A1/es
Priority to AT00976087T priority patent/ATE295162T1/de
Priority to AU13979/01A priority patent/AU1397901A/en
Priority to DE60020111T priority patent/DE60020111T2/de
Priority to EP00976087A priority patent/EP1177790B1/en
Priority to ES00976087T priority patent/ES2241670T3/es
Publication of ES2164584A1 publication Critical patent/ES2164584A1/es
Priority to US10/647,739 priority patent/US20040039048A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Terapia con cannabinoides para el tratamiento de tumores cerebrales. La terapia con cannabinoides para el tratamiento de tumores cerebrales consiste en la administración (intracraneal o sistémica) de cannabinoides (naturales o sintéticos) a mamíferos (humanos o no humanos) portadores de tumores cerebrales. Los cannabinoides conducen, mediante la activación de sus receptores específicos, a la muerte selectiva de las células transformadas. Se consigue así la regresión o erradicación de tumores cerebrales sin efectos colaterales significativos.
ES200000323A 2000-02-11 2000-02-11 Terapia con cannabinoides para el tratamiento de tumores cerebrales. Pending ES2164584A1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES200000323A ES2164584A1 (es) 2000-02-11 2000-02-11 Terapia con cannabinoides para el tratamiento de tumores cerebrales.
AT00976087T ATE295162T1 (de) 2000-02-11 2000-11-22 Therapeutische anwendung von cannabinoiden zur hirntumorbehandlung
AU13979/01A AU1397901A (en) 2000-02-11 2000-11-22 Therapy with cannabinoids in the treatment of cerebral tumor
DE60020111T DE60020111T2 (de) 2000-02-11 2000-11-22 Therapeutische anwendung von cannabinoiden zur hirntumorbehandlung
EP00976087A EP1177790B1 (en) 2000-02-11 2000-11-22 Therapy with cannabinoids in the treatment of cerebral tumor
ES00976087T ES2241670T3 (es) 2000-02-11 2000-11-22 Terapia con cannabinoides para el tratamiento de tumores cerebrales.
US10/647,739 US20040039048A1 (en) 2000-02-11 2003-08-25 Therapy with cannabinoid compounds for the treatment of brain tumors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200000323A ES2164584A1 (es) 2000-02-11 2000-02-11 Terapia con cannabinoides para el tratamiento de tumores cerebrales.

Publications (1)

Publication Number Publication Date
ES2164584A1 true ES2164584A1 (es) 2002-02-16

Family

ID=8492270

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200000323A Pending ES2164584A1 (es) 2000-02-11 2000-02-11 Terapia con cannabinoides para el tratamiento de tumores cerebrales.
ES00976087T Expired - Lifetime ES2241670T3 (es) 2000-02-11 2000-11-22 Terapia con cannabinoides para el tratamiento de tumores cerebrales.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00976087T Expired - Lifetime ES2241670T3 (es) 2000-02-11 2000-11-22 Terapia con cannabinoides para el tratamiento de tumores cerebrales.

Country Status (5)

Country Link
EP (1) EP1177790B1 (es)
AT (1) ATE295162T1 (es)
AU (1) AU1397901A (es)
DE (1) DE60020111T2 (es)
ES (2) ES2164584A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2460672B (en) * 2008-06-04 2012-01-04 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2516814B (en) * 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
WO2019034936A2 (en) 2017-08-13 2019-02-21 Buzzelet Development And Technologies Ltd TERPENE ENRICHED CANNABINOID COMPOSITION AND PROCESSING METHOD

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAEK SEUNG-HWA et al.: "Boron trifluoride etherate on silica - A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells", Arch. Pharmacol. Res. (Seul), junio 1998, Volumen 21 (3), paginas 353-356; paginas 354-356, resultados y discusion. *
BAEK SEUNG-HWA et al.: "Synthesis and antitumor activity of cannabigerol", Arch. Pharmacol. Res., Volumen 19, paginas 228-230; paginas 228,229. *
HARRIS, L.S. et al.: "Anti-tumor properties of cannabinoids", BRAUDE, M.C. & STEPHEN SZARA (ED.) "Pharmacology of marihuana", Volumenes 1 y 2, A monograph of the National Institute of Drug Abuse. Proceedings of the Meeting Savanah, GA, USA, diciembre 3-6, 1974. Illus. Raven Press: Nueva York, EEUU, ISBN 0-89004-067-2, 1976, paginas 749-762; pagina 753, lineas 4-10. *
HARRIS, L.S. et al.: "Retardation of tumor growth by delta-9-tetrahydrocannabinol", The Pharmacologist (1974), Volumen 16 (2), pagina 259; resumen. *
RUIZ, L. et al.: "Delta-9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism", FEBS Lett. (1999), Volumen 458 (3), paginas 400-404. ISSN: 0253-5823. *

Also Published As

Publication number Publication date
ATE295162T1 (de) 2005-05-15
EP1177790A1 (en) 2002-02-06
ES2241670T3 (es) 2005-11-01
AU1397901A (en) 2001-08-20
DE60020111D1 (de) 2005-06-16
EP1177790B1 (en) 2005-05-11
DE60020111T2 (de) 2006-03-09

Similar Documents

Publication Publication Date Title
ES2149971T3 (es) Derivados 5-sustituidos del acido micofenolico.
CO4770978A1 (es) Empleo de epinastina para el tratamiento de dolores
PA8600601A1 (es) Ligandos de receptores de cannabinoides y sus usos
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
EP1363632A4 (en) SELECTIVE CANNABIMIMETIC AMINOALKYLINDOLES OF A RECEPTOR
ES2045061T3 (es) Metodo de medicion del contenido de humedad en la piel, y aparato para aplicar dicho metodo.
AR030236A1 (es) Moléculas similares a il-17 y usos de las mismas
PA8553001A1 (es) Compuestos biciclicos aromaticos sustituidos con amino-alquilo, procedimiento para su preparacion y su utilizacion como medicamentos.
ES2164584A1 (es) Terapia con cannabinoides para el tratamiento de tumores cerebrales.
CR7168A (es) Ligandos del receptor de 5.ht y sus usos
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
AR009507A1 (es) Utilizacion de retinoides
CU23535A3 (es) Compuestos de purina y usos de los mismos
UY26150A1 (es) Inhibidores de cinasas, de pirrolotriazina ley 17164
AR035284A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
ES2161442T3 (es) Analogos de coralina como inhibidores de topoisomerasa.
HN2000000051A (es) Derivados heterociclicos utiles como agentes anticancerosos
ES2081366T3 (es) Uso de la il-7 en la preparacion de medicaciones para estimular la produccion de plaquetas.
AR025885A1 (es) Derivados del acido indolil-3-glioxilico con valiosas propiedades terapeuticas
ES2194918T3 (es) Compuestos de tiazol y tiadiazol como ligando receptor de dopamina d3.
BR0215404A (pt) processo e dispositivo para reduzir dosagem terapêutica
ES2189992T3 (es) Reduccion del crecimiento del pelo.
ES2151517T3 (es) Efectos de filamentos de actina sobre la estructura y lisis de coagulos de fibrina.
BR0114430A (pt) Processos para a indução da morte de células cancerìgenas e para a regressão de tumor
ES2167356T3 (es) Utilizacion de tioureilenos y tiabendazol en enfermedades autoinmunitarias e inflamatorias de la piel.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020216

Kind code of ref document: A1

Effective date: 20020216

FC2A Grant refused

Effective date: 20040520